8-K/ALeadership Changes

GILEAD SCIENCES, INC. 8-K/A Report, Executive Changes (Aug 14, 2008)

Filed August 14, 2008For Securities:GILD

Summary

This Form 8-K/A filing from Gilead Sciences, Inc. (GILD) serves as an amendment to a previous 8-K filing on August 5, 2008, concerning the election of Dr. Richard J. Whitley to the Board of Directors. The amendment provides additional disclosures regarding Dr. Whitley's prior business relationship with the company, specifically outlining consulting services provided by his company, Viral Interventions, Inc., and by Dr. Whitley himself. These services, related to health policy and strategic consulting, were engaged in on a discrete project basis. Investors should note that the aggregate payments made to Viral Interventions, Inc. and Dr. Whitley individually for these consulting services between January 1, 2007, and July 31, 2008, amounted to approximately $255,329. Importantly, as of Dr. Whitley's appointment to the Board, Viral Interventions, Inc. has ceased providing services to Gilead. This disclosure aims to ensure transparency regarding potential related-party transactions and director independence.

Key Highlights

  • 1Gilead Sciences filed an 8-K/A (Amendment No. 1) on August 14, 2008.
  • 2The filing amends a prior 8-K dated August 5, 2008, regarding the election of Richard J. Whitley, MD, to the Board of Directors.
  • 3Additional disclosures are provided regarding Dr. Whitley's prior business relationship with Gilead Sciences.
  • 4Dr. Whitley's company, Viral Interventions, Inc., provided health policy and strategic consulting services.
  • 5Payments to Viral Interventions, Inc. and Dr. Whitley individually for consulting services totaled $165,485.39 and $89,843.90 respectively, between January 1, 2007, and July 31, 2008.
  • 6Viral Interventions, Inc. ceased providing services to Gilead as of Dr. Whitley's appointment to the Board.

Frequently Asked Questions

The primary purpose of this filing is to provide additional disclosures regarding the background and prior business relationship of Dr. Richard J. Whitley, who was recently elected to Gilead's Board of Directors. It amends a previous 8-K to ensure full transparency around any potential related-party transactions.

Dr. Whitley's company, Viral Interventions, Inc., provided discrete health policy and strategic consulting services to Gilead Sciences. Dr. Whitley himself also provided consulting services to the company.

Between January 1, 2007, and July 31, 2008, Gilead paid Viral Interventions, Inc. a total of $165,485.39 and Dr. Whitley individually $89,843.90 for these consulting services, totaling approximately $255,329.

No, the filing explicitly states that Viral Interventions, Inc. ceased performing services for Gilead as of the date of Dr. Whitley's appointment to the Board of Directors.